Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention

Simply Wall St.

02/12

Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026. The launches span high content screening, plate reading, and laboratory automation tools. The new products ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610899115"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610899115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610899115?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-02-12 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610899115","market":"hk","top_or_hot":-1,"title":"Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention","media":"Simply Wall St.","content":"<div>\n<p>Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026. The launches span high content screening, plate reading, and laboratory automation tools. The new products ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-unveils-slas2026-platforms-as-valuation-gap-attracts\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-02-12 09:21</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026. The launches span high content screening, plate reading, and laboratory automation tools. The new products ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-unveils-slas2026-platforms-as-valuation-gap-attracts\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-unveils-slas2026-platforms-as-valuation-gap-attracts\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-unveils-slas2026-platforms-as-valuation-gap-attracts","article_id":"2610899115","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-unveils-slas2026-platforms-as-valuation-gap-attracts","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610899115","pubTimestamp":1770859275,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026.\nThe launches span high content screening, plate reading, and laboratory automation tools.\nThe new products are designed to support faster drug discovery and streamlined lab workflows.\n\nRevvity, trading at around $101.1, is adding fresh products to its life sciences tools portfolio at a time when its 1 year return sits at a decline of 8.9% and its 3 year and 5 year returns show declines of 24.7% and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4121":"生命科学工具和服务","RVTY":"REVVITY INC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4588":"碎股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC"},"translate_title":"估值差距引起关注，Revvity推出SLAS2026平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":1},"content_text":"Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026. The launches span high content screening, plate reading, and laboratory automation tools. The new products are designed to support faster drug discovery and streamlined lab workflows.  Revvity, trading at around $101.1, is adding fresh products to its life sciences tools portfolio at a time when its 1 year return sits at a decline of 8.9% and its 3 year and 5 year returns show declines of 24.7% and 29.2% respectively. For investors tracking NYSE:RVTY, these launches at a major industry conference highlight how the company is positioning its technology stack in high content screening and automated lab workflows. Going forward, you might watch how quickly these platforms gain traction with pharma, biotech, and academic labs, and whether they integrate into existing discovery workflows. Adoption patterns, recurring revenue potential, and any follow-up product iterations could all become useful signals for how meaningful SLAS2026 is for Revvity's broader tools franchise. Stay updated on the most important news stories for Revvity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Revvity. NYSE:RVTY Earnings & Revenue Growth as at Feb 2026 We've flagged 1 risk for Revvity. See which could impact your investment. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$101.10, the share price sits about 15% below the US$119.56 analyst target range midpoint. ✅ Simply Wall St Valuation: Shares are described as trading 27.4% below estimated fair value, which flags a potential valuation gap. ❌ Recent Momentum: The 30 day return of about 2.7% decline shows the market has been cautious recently.  There is only one way to know the right time to buy, sell or hold Revvity. Head to Simply Wall St's\ncompany report for the latest analysis of Revvity's Fair Value. Key Considerations  📊 The SLAS2026 platform launches sit alongside a relatively high P/E of 47.8 and life sciences positioning, so you may want to judge whether the product suite justifies that earnings multiple. 📊 Watch how any commentary links new tools to revenue growth, recurring software or consumables, and whether analysts adjust the US$105 to US$140 target range. ⚠️ One flagged risk is large one off items affecting reported earnings quality, which can make it harder to read the true impact of new platforms on profitability.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Revvity analysis. Alternatively, you can visit the\ncommunity page for Revvity to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}